1-3 of 3
Lili Zhu, MS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039)

Stephen Ansell, MD PhD, Martin E Gutierrez, MD, Margaret A. Shipp, MD, Douglas Gladstone, MD, Alison Moskowitz, Ivan Borello, Mihaela Popa-Mckiver, Benedetto Farsaci, Lili Zhu, MS, Alexander M. Lesokhin, MD, Philippe Armand, MD PhD
Journal: Blood
Blood (2016) 128 (22): 183.
https://doi.org/10.1182/blood.V128.22.183.183
Published: 2016
Journal Articles

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma

Philippe Armand, MD PhD, Pier Luigi Zinzani, MD PhD, Graham P. Collins, MD PhD, Jonathon B. Cohen, MD, Ahmad S. Halwani, MD, Carmelo Carlo-Stella, MD, Michael M. Millenson, MD, Mariano Provencio, MD PhD, Eva Domingo Domenech, MD, Lisa Giulino Roth, MD, Luca Castagna, MD, Kazunobu Kato, MD, Mihaela Popa McKiver, Anne Sumbul, Lili Zhu, MS, Armando Santoro, MD
Journal: Blood
Blood (2016) 128 (22): 3502.
https://doi.org/10.1182/blood.V128.22.3502.3502
Published: 2016
Journal Articles

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study (CA209-039)

Stephen Ansell, MD PhD, Philippe Armand, MD PhD, John M. Timmerman, MD, Margaret A. Shipp, MD, M Brigid Bradley Garelik, MD, Lili Zhu, MS, Alexander M. Lesokhin, MD
Journal: Blood
Blood (2015) 126 (23): 583.
https://doi.org/10.1182/blood.V126.23.583.583
Published: 2015